Table 3. Cost parameters*.
| Costs | Mean (THB)† | Distribution§ | Reference |
|---|---|---|---|
| Antiviral combination therapy (per course) | |||
| PEG-RBV for 24 weeks | 75,600 | Gamma | Drug companies |
| PEG-RBV for 48 weeks | 151,200 | Gamma | Drug companies |
| SOF + PEG-RBV for 12 weeks | 163,800 | Gamma | Drug companies |
| SOF + DCV for 12 weeks | 252,000 | Gamma | Drug companies |
| SOF + LDV for 12 weeks | 166,500 | Gamma | Drug company |
| Laboratory tests for investigation and monitoring (per course) | |||
| HCV genotype testing | 5,410 | Gamma | [36] |
| PEG-RBV for 24 weeks | 17,100 | Gamma | [36, 37] |
| PEG-RBV for 48 weeks | 20,200 | Gamma | [36, 37] |
| SOF + PEG-RBV for 12 weeks | 8,700 | Gamma | [36, 37] |
| SOF + DCV for 12 weeks | 8,700 | Gamma | [36, 37] |
| SOF + LDV for 12 weeks | 14,100 | Gamma | [36, 37] |
| Treatment costs of HCV complication (per year) | |||
| Chronic HCV infection | 72,000 | Gamma | [38] |
| Compensated cirrhosis | 80,000 | Gamma | [38] |
| Decompensated cirrhosis | 148,300 | Gamma | [38] |
| Hepatocellular carcinoma | 183,800 | Gamma | [38] |
| Anemia | 8,317 | Gamma | [36, 39] |
| Direct-non medical costs | |||
| Chronic HCV infection (per year) | 4,470 | Gamma | [36] |
| Compensated cirrhosis (per year) | 4,380 | Gamma | [36] |
| Decompensated cirrhosis (per year) | 6,060 | Gamma | [36] |
| Hepatocellular carcinoma (per year) | 9,900 | Gamma | [36] |
| Hospital visit, outpatient service (per visit) | 670 | Gamma | [36] |
*The number is rounded up.
†Sum of the aggregate amount of costs; standard errors of unit costs are not reported.
§ Probability distribution for employing uncertainty analysis in economic evaluation
THB—Thai Baht